(281) 713-2962
800 Rockmead Drive, Suite 155
Kingwood, TX 77339
[email protected]
Impact of CardiolRx on Recurrent Pericarditis
Status: Not yet recruiting
Location:
Conditions:
City/State:
Rochester, Minnesota
Cleveland, Ohio
Contact Information:
S. A. Luis, MD [email protected]
Sonya Mihalus, BSN [email protected]
Patients with recurrent pericarditis who are refractory or intolerant to current therapeutic management options or who require long-term administration of corticosteroids to control their disease are particularly challenging to manage. The pathogenesis of pericarditis involves the activation of the inflammasome. CardiolRxTM (a pure cannabidiol [CBD] solution) is known to have anti-inflammatory properties, including modulation of inflammasome signaling. This pilot study is to assess the tolerance and safety of CardiolRxTM during the resolution of pericarditis symptoms, assess improvement in objective measures of disease, and during the extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids while taking CardiolRxTM.
Read moreEffcacy and Safety of RPH-104 Treatment in Patients with Recurrent Pericarditis
Status: Not yet recruiting
Location: Virginia Commonwealth University
Conditions: Virginia Commonwealth University
City/State:
Richmond, Virginia
Contact Information:
Antonio Abbate, MD 804-828-0513 [email protected]
“The primary purpose of this study is the evaluation of the efficacy and safety of RPH-104 treatment in patients with recurrent pericarditis.
Pharmacokinetic and pharmacodynamic parameters of RPH-104 multiple doses in this patient population will be assessed as well.”
MYTHS – MYocarditis THerapy with Steroids
Status: Not yet recruiting
Location: University of California San Diego, Virginia Commonwealth University
Conditions: University of California San Diego, Virginia Commonwealth University
City/State:
San Diego, California
Richmond, Virginia
Contact Information:
Eric D Adler, MD
Antonio Abbate, MD
This is a phase III, multi-center international, single blind randomized controlled trial to test the efficacy of pulsed intravenous (IV) methylprednisolone versus standard therapy on top of maximal support in patients with Acute myocarditis (AM).
Read moreThe ORCHESTRATE – Myocarditis Registry
Status: Not yet recruiting
Location: Kansas City Heart Rhythm Institute, Loma Linda University International Heart Institute, Montefiore Medical Center, Texas Cardiac Arrhythmis Institute at St. David's Medical Center
Conditions: Kansas City Heart Rhythm Institute, Loma Linda University International Heart Institute, Montefiore Medical Center, Texas Cardiac Arrhythmis Institute at St. David's Medical Center
City/State:
Loma Linda, California
Overland Park, Kansas
Bronx, New York
Austin Texas
Contact Information:
Jalaj Garg, MD 585-766-0898 [email protected]
Dhanunjaya Lakkireddy, MD 913-449-1297 [email protected]
Luigi Di Biase, MD 718-920-4321 [email protected]
Andrea Natale, MD 512-807-3150 [email protected]
A retrospective, observational study consisting of patients who presents with typical/atypical chest pain and have an ensuing negative ischemic evaluation
Read moreMyocarditis Causing Premature Ventricular Contractions: Insights From the MAVERIC Registry
Status: Not yet recruiting
Location: Mayo Clinic in Rochester
Conditions: Mayo Clinic in Rochester
City/State:
Rochester, Minnesota
Contact Information:
Sierra Slade, 507-422-5433, [email protected]
Trevor Stromme, 507-293-2754, [email protected]
Hypothesized that occult inflammation is clinically under-recognized in patients with symptomatic PVCs with and without Left ventricular (LV) dysfunction and can be a potential link between the 2 conditions. Aimed to evaluate the incidence of underlying inflammation using the Positron emission tomography (PET) scan in patients presenting with symptomatic PVCs enrolled retrospectively in the MAVERIC registry.
Rheumatoid arthritis (RA) patients have a higher prevalence of subclinical atherosclerosis than the general population. In addition, RA patients experience higher rates of heart failure with preserved ejection fraction (HFpEF). There is evidence that myocardial mechanics and left ventricular diastolic function are more abnormal in the RA population and these changes occur earlier than in the general population. Recently a study suggested that RA patient have abnormal myocardial inflammation during a disease flare and that this is improved with anti-inflammatory treatment. This study is aimed at describing the prevalence of myocardial inflammation in patients during active RA disease flares and comparing that with RA patients who are in remission. Investigators hope to show that abnormalities in myocardial inflammation on PET imaging correlate with abnormalities in myocardial strain on echocardiography. Coronary CT will be performed to establish the presence of subclinical atherosclerosis and whether its presence affects changes in either myocardial inflammation or myocardial strain. The hypothesis is that patients with evidence of myocardial inflammation during the course of their RA disease are more likely to develop HFpEF during their lifetime. Although the present study will not be of a duration to assess outcome, it will provide descriptive data which may help guide future prospective study of patients with RA which may help guide appropriate cardiovascular testing in this high risk population.
Read more